Every 10-Q that Apogee Therapeutics Inc (APGE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow APGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APGE filings page.
Apogee Therapeutics is a clinical-stage biotechnology company developing biologic therapies for inflammatory and immunology indications, including atopic dermatitis and asthma. It reported a net loss of $85.9 million for the quarter and $160.0 million for the six months ended June 30, 2026, driven mainly by research and development spending.
Cash and cash equivalents were $105.6 million, with additional marketable securities of $866.4 million current and $321.9 million long term, bringing total assets to $1.34 billion. Management estimates this liquidity will fund operating expenses and capital needs for at least 12 months.
Apogee entered an Agreement and Plan of Merger under which a subsidiary of AbbVie will merge with Apogee, leaving it a wholly owned subsidiary, subject to stockholder and regulatory approvals. It also closed a $100.0 million revenue share financing with Blackstone Life Sciences tied to future net sales of zumilokibart, recorded as a $99.2 million revenue share liability with a 16.4% effective interest rate.
Apogee Therapeutics reported a larger quarterly net loss as it continues to invest heavily in its inflammatory and immunology pipeline. For the three months ended March 31, 2026, net loss was $74.1M compared with $55.3M a year earlier, driven by higher research and development and general and administrative expenses.
R&D spending rose to $60.8M from $46.4M, while G&A increased to $22.0M from $16.7M. The company ended the quarter with substantial liquidity, including $451.8M in cash and cash equivalents, $608.1M in marketable securities and $198.4M in long‑term marketable securities, and believes this will fund operations for at least 12 months. Apogee also highlights positive Phase 2 data for its lead antibody zumilokibart in atopic dermatitis, supporting its strategy to develop differentiated biologics across major inflammatory indications.
Apogee Therapeutics (APGE) filed its Q3 2025 report, showing a net loss of $65.0 million, driven by operating expenses of $71.3 million. Research and development was $54.2 million and general and administrative was $17.1 million. Interest income contributed $6.3 million.
Liquidity remained strong with cash and cash equivalents of $107.9 million, marketable securities of $419.4 million, and long-term marketable securities of $61.6 million as of September 30, 2025. The company recorded stockholders’ equity of $586.3 million and an accumulated deficit of $492.4 million. Management states these resources will fund operations for at least the next 12 months. Capital actions included $19.4 million of net proceeds from the at-the-market program in Q3 and, subsequently, approximately $324.1 million of net proceeds from an October 2025 underwritten offering of common stock and pre-funded warrants. As of November 3, 2025, shares outstanding were 68,320,229, including 54,833,587 voting and 13,486,642 non-voting shares.
Apogee Therapeutics (APGE) is a clinical-stage biotech focused on inflammatory and immunology targets. The company reported a six-month net loss of $121.4 million and an accumulated deficit of $427.4 million. Research and development expense rose sharply to $102.1 million for the six months ended June 30, 2025 (compared with $61.9 million a year earlier), while general and administrative was $34.2 million.
The balance sheet shows $124.2 million of cash and cash equivalents, $381.2 million of current marketable securities and $115.8 million of long-term marketable securities, totaling roughly $621.2 million of liquidity. Operating cash used was $110.5 million in the first six months of 2025, and management states these resources should fund operations for at least the next 12 months. The company continues to advance multiple programs (IL-13, IL-4Rα, OX40L, TSLP) under licenses from Paragon and maintains manufacturing and supply agreements with WuXi Biologics and Samsung Biologics, with related milestone and service payments disclosed.